Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors
Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company formed by TPG Capital, today announced that David Kessler, M.D., and John Fraher have joined the companys newly established Board of Directors. Dr. Kessler and Fraher will serve on the companys inaugural board alongside CEO Troy Hamilton and three members of the TPG Capital team: John Schilling, M.D., Todd Sisitsky, and Katherine Wood. The formation of the board follows the recent creation of Ellodi Pharmaceuticals, which was established in September 2020 through a transaction that spun-out select clinical assets from Adare Pharmaceuticals. Launched in partnership with former members of Adares clinical leadership team, Ellodi Pharmaceuticals is dedicated to the continued development of APT-1011, a novel therapy in